Glucose excursions in type 2 diabetes modulate amyloid-related proteins associated with dementia by Moin, Abu Saleh Md et al.
Moin et al. J Transl Med          (2021) 19:131  
https://doi.org/10.1186/s12967-021-02797-3
LETTER TO THE EDITOR
Glucose excursions in type 2 diabetes 
modulate amyloid-related proteins associated 
with dementia
Abu Saleh Md Moin1, Ahmed Al‑Qaissi2,3, Thozhukat Sathyapalan2, Stephen L. Atkin4†  
and Alexandra E. Butler1*†  
Keywords: Type 2 diabetes, Glucose variability, Amyloid‑associated proteins, Alzheimer’s disease
© The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, 
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and 
the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material 
in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material 
is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds 
the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://crea‑
tivecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdo‑
main/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
To the Editor:
We have reported that hypoglycemia was associated with 
changes in Alzheimer’s disease (AD)-related proteins [1] 
in accord with the direct link of cognitive dysfunction to 
hypoglycemia. Dementia is a recognized complication 
of type 2 diabetes (T2D) with an increasing prevalence, 
and AD is the most common cause. However, whilst the 
stress induced by hypoglycemia was likely the trigger, 
the contribution of the fall in glucose alone was unclear, 
given that glucose variability is associated with lower 
level cognitive function [2].
A case-controlled study was undertaken, enroll-
ing type 2 diabetes (T2D) and control subjects. As 
detailed previously, each subject fasted for 10-h prior 
to undergoing a hyperinsulinemic clamp [3]. The 
mean baseline plasma glucose in the T2D cohort was 
7.6 ± 0.4  mmol/l (136.8 ± 7.2  mg/dl); this was decreased 
to 4.5 ± 0.07  mmol/l (81 ± 1.2  mg/dl) for a duration of 
1-h. For the control cohort, the mean plasma glucose 
was maintained at the baseline level of 4.9 ± 0.1 mmol/l 
(88.2 ± 1.8  mg/dl). To determine plasma levels of Alz-
heimer disease-related proteins, Slow Off-rate Modified 
Aptamer (SOMA)-scan measurement was undertaken, as 
previously detailed [3]. This analysis incorporated fifteen 
Alzheimer disease-related proteins: Serum amyloid A1 
[SAA1], Alpha-synuclein [SNCA], Pappalysin [PAPPA], 
Noggin, Amyloid precursor protein [APP], Amyloid P 
component [APCS], Microtubule-associated protein 
tau [MAPT], Clusterin [CLU], Complement C3 (C3), 
Apolipoprotein A1 [ApoA1], Apolipoprotein B [ApoB], 
Apolipoprotein E [ApoE], Apolipoprotein E2 [ApoE2], 
Apolipoprotein E3 [ApoE3], Apolipoprotein E4 [ApoE4]. 
Graphpad Prism 8.0 was utilized to perform statistical 
analysis.
Age was comparable between T2D (n = 23) and control 
(n = 23) subjects (p = ns); as a group, the T2D cohort had 
an elevated BMI (p = 0.0012) with T2D disease duration 
4.5 ± 2.9 years.
AD-related protein changes are shown in Fig.  1. APP 
was elevated at baseline (p < 0.01), and SNCA (p < 0.01) 
and ApoB (p < 0.05) decreased, in T2D whilst there was 
no difference between controls and T2D subjects at base-
line for the other AD-related proteins. Following the 
hyperinsulinaemic clamp, APOA1 and C3 were signifi-
cantly reduced (p = 0.05).
At baseline, the T2D cohort had higher circulating 
APP and lower SNCA; these results accorded with the 
findings in a previous report detailing circulating pro-
tein levels in AD [1]: accumulations of β-amyloid (Aβ) 
and tau proteins in the brain are pathognomonic of AD, 
and these deposits are believed to be a central facet in 
the pathophysiology of developing AD. It has been sug-
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of rare coding variants of ApoB [4]. The protein com-
ponent of HDL is comprised mainly of ApoA1; higher 
circulatory HDL/ApoA1 levels have been linked with 
decreased risk for AD and dementia [1]. Here, ApoA1 
showed an increase with normoglycemia in T2D, but 
not in controls, suggesting that glucose normalisation 
was beneficial; future studies should study how glu-
cose modulation affects ApoA1 levels. Conversely, C3 
decreased with normoglycemia in T2D, but not con-
trols. In the Copenhagen study of 95,442 individuals, 
lower complement C3 levels associated with higher risk 
for AD [5], suggesting that the fall in C3 with glucose 
normalisation may not be of benefit. ApoA1 concentra-
tions have been positively correlated with circulating 
C3 [6], perhaps explaining why changes were seen for 
both, and their serum dysregulation has been reported 
in AD [6]. Glucose normalisation, falling by 55  mg/
dl, occurred here and it is unclear whether the abso-
lute glucose excursion or the rate of change of glucose 
were responsible for ApoA1 and C3 changes, and this 
requires clarification.
Study strengths include that T2D subjects had a rela-
tively short duration of disease and were on minimal 
anti-diabetic therapy. Study limitations are the relatively 
small subject numbers and the small decrease in glucose 
for a short timeframe undertaken with the clamp.
In conclusion, AD-related proteins were lower in dia-
betes, and ApoA1 increased whilst C3 decreased signifi-
cantly with euglycemia, suggesting that changes in these 
proteins may contribute to cognitive changes and this 




Fig. 1 Circulatory levels of Alzheimer Disease (AD)‑related proteins at baseline and upon glucose level normalization in T2D subjects. Blood 
sampling was performed at baseline (BL) in both controls (white circles) and T2D (black squares), and at glucose normalization (BM) in T2D 
subjects. At baseline (BL), blood sugar (BS) was 7.5 ± 0.4 mM (for T2D) and 5.0 ± 0.1 mM (for control, C). Proteomic (Somalogic) analysis of 
amyloid‑related proteins was undertaken for fifteen amyloid‑related proteins included in this analysis: Amyloid precursor protein [APP], Amyloid 
P component [APCS], Noggin, Alpha‑synuclein [SNCA], Microtubule‑associated protein tau [MAPT], Pappalysin [PAPPA] and Serum amyloid A1 
[SAA1], Apolipoprotein A1 [ApoA1], Apolipoprotein B [ApoB], Apolipoprotein E [ApoE], Apolipoprotein E2 [ApoE2], Apolipoprotein E3 [ApoE3], 
Apolipoprotein E4 [ApoE4], Clusterin [CLU] and complement C3 (C3). Only proteins with changes at baseline between T2D and controls, or changes 
between BL and BM in T2D. Statistics: T2D vs control at BL: ^p < 0.05, *p < 0.01; T2D BL vs BM: $p < 0.05. RFU, relative fluorescent units
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